Stockscreener 앱 받기
0.7295
1.03%
-0.0076
전일 마감가:
$0.7371
열려 있는:
$0.7555
하루 거래량:
3.68M
Relative Volume:
0.79
시가총액:
$157.94M
수익:
-
순이익/손실:
$-111.13M
주가수익비율:
-0.5527
EPS:
-1.32
순현금흐름:
$-91.53M
1주 성능:
-4.59%
1개월 성능:
-4.64%
6개월 성능:
+1.22%
1년 성능:
-47.52%
1일 변동 폭
$0.7151
$0.765
1주일 범위
$0.70
$0.792
52주 변동 폭
$0.36
$2.35
Tenaya Therapeutics Inc Stock (TNYA) Company Profile
명칭
Tenaya Therapeutics Inc
전화
415-865-2066
주소
171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO
TNYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNYA
Tenaya Therapeutics Inc
|
0.7295 | 159.59M | 0 | -111.13M | -91.53M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Tenaya Therapeutics Inc Stock (TNYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-06-10 | 개시 | William Blair | Outperform |
| 2023-11-30 | 개시 | Leerink Partners | Outperform |
| 2022-06-15 | 개시 | H.C. Wainwright | Buy |
Tenaya Therapeutics Inc 주식(TNYA)의 최신 뉴스
9 Overlooked Growth Stocks to Buy - Insider Monkey
Morgan Stanley reduces PT on Tenaya Therapeutics (TNYA), keeps constructive stance on US small- to mid-cap biotech - MSN
Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech - Insider Monkey
Tenaya Therapeutics appoints new interim principal accounting officer - MSN
10 Stocks Under $1 That Will Explode - Insider Monkey
What catalysts could drive Tenaya Therapeutics Inc. stock higher2025 Trading Volume Trends & Fast Entry High Yield Tips - Улправда
Will Tenaya Therapeutics Inc. stock benefit from infrastructure spending2025 Macro Impact & Free Real-Time Market Sentiment Alerts - ulpravda.ru
Tenaya Therapeutics announces 2026 strategic priorities - MarketScreener
Tenaya Therapeutics Outlines 2026 Milestones Following Positive Interim Results from MyPEAK™-1 and RIDGE™-1 Trials - Quiver Quantitative
Gene therapy trials for inherited heart disease face big 2026 tests - Stock Titan
Is Tenaya Therapeutics Inc. stock supported by strong fundamentalsInflation Watch & Proven Capital Preservation Tips - ulpravda.ru
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones - Yahoo Finance
Why Tenaya Therapeutics Inc. stock could see breakout soonJuly 2025 Drop Watch & Consistent Income Trade Recommendations - Улправда
Published on: 2026-01-09 09:18:13 - Улправда
What insider trading reveals about Tenaya Therapeutics Inc. stockEntry Point & Consistent Return Investment Signals - Улправда
Published on: 2026-01-09 03:34:26 - Bộ Nội Vụ
Why Tenaya Therapeutics Inc. stock is trending among retail tradersJuly 2025 Rallies & Free Accurate Trade Setup Notifications - Улправда
How Tenaya Therapeutics Inc. stock reacts to Fed rate cutsEarnings Beat Highlights & Affordable Portfolio Building - ulpravda.ru
Tenaya Therapeutics announces orderly board leadership transition - MSN
Tenaya Therapeutics Inc. (TNYA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Buy Signal: Is Tenaya Therapeutics Inc stock supported by strong fundamentalsPortfolio Update Report & Daily Volume Surge Signals - moha.gov.vn
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Tenaya Therapeutics price target lowered to $4 from $6 at Canaccord - MSN
Why Tenaya Therapeutics Inc. stock is rated strong buy2025 Price Momentum & Free Expert Verified Stock Movement Alerts - Bölüm Sonu Canavarı
Tenaya Therapeutics, Inc.(NasdaqGS: TNYA) added to NASDAQ Biotechnology Index - MarketScreener
Buyout Rumor: Why Tenaya Therapeutics Inc stock is recommended by analystsMarket Activity Report & Reliable Trade Execution Plans - moha.gov.vn
Is International Seaways Inc stock attractive for ETFsMarket Risk Analysis & Smart Money Movement Tracker - moha.gov.vn
Leerink Partners Reaffirms Their Buy Rating on Tenaya Therapeutics (TNYA) - The Globe and Mail
Will Tenaya Therapeutics Inc. stock outperform growth indexesWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Is Tenaya Therapeutics Inc. stock positioned for long term growth2025 Performance Recap & Low Drawdown Momentum Ideas - Улправда
Will Tenaya Therapeutics Inc. stock remain a Wall Street favorite2025 Top Gainers & Consistent Profit Trading Strategies - DonanımHaber
Will Tenaya Therapeutics Inc. stock deliver shareholder valueQuarterly Investment Review & Expert-Curated Trade Recommendations - DonanımHaber
Canaccord Genuity Keeps Their Buy Rating on Tenaya Therapeutics (TNYA) - The Globe and Mail
Tenaya Therapeutics stock price target lowered to $5 at Canaccord By Investing.com - Investing.com Canada
FY2025 Earnings Forecast for TNYA Issued By Lifesci Capital - MarketBeat
Tenaya Therapeutics stock price target lowered to $5 at Canaccord - Investing.com India
Wilson Sonsini Advises Tenaya Therapeutics on Pricing of Public Offering - Wilson Sonsini
H.C. Wainwright lowers Tenaya Therapeutics stock price target to $3 on ARVC trial data By Investing.com - Investing.com Australia
Tenaya fundraising follows resolution of clinical hold - The Pharma Letter
H.C. Wainwright lowers Tenaya Therapeutics stock price target to $3 on ARVC trial data - Investing.com Nigeria
Tenaya Therapeutics announces proposed public offering - MSN
Tenaya Therapeutics price target lowered to $3 from $5 at HC Wainwright - MSN
Tenaya Therapeutics Inc (TNYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tenaya Therapeutics Inc 주식 (TNYA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Tingley Whittemore | Chief Medical Officer |
Nov 17 '25 |
Sale |
1.33 |
2,877 |
3,826 |
169,926 |
| Ali Faraz | Chief Executive Officer |
Nov 17 '25 |
Sale |
1.33 |
3,126 |
4,158 |
299,666 |
| Higa Tomohiro | SVP, Finance |
Aug 18 '25 |
Sale |
1.25 |
2,962 |
3,711 |
95,338 |
| Tingley Whittemore | Chief Medical Officer |
Aug 18 '25 |
Sale |
1.25 |
5,053 |
6,331 |
172,803 |
| Ali Faraz | Chief Executive Officer |
Aug 18 '25 |
Sale |
1.25 |
14,533 |
18,210 |
302,792 |
4.73%
0.92%
자본화:
|
볼륨(24시간):